Archives
-
Calnexin and Variant-Specific CFTR Rescue
2026-10-06
Tedman et al. use deep mutational scanning to examine how the ER chaperone calnexin influences expression and pharmacological rescue across 232 clinical CFTR variants. Their findings show that proteostasis is a major, variant-dependent determinant of plasma membrane delivery and corrector responsiveness, while also separating protein abundance effects from channel function.
-
LMO2–LDB1 Signaling in Acute Myeloid Leukemia
2026-10-06
A 2023 study identifies an LMO2/LDB1 protein complex as a functional contributor to acute myeloid leukemia (AML) cell proliferation and survival. By combining genetic perturbation, protein-interaction analysis, in vivo evidence, RNA-seq, and ChIP-seq, the work links LDB1-dependent transcriptional regulation with apoptosis-related programs while showing that LMO2 can partially compensate for LDB1 loss.
-
Ciprofloxacin in TNBC Nanotheranostics Research
2026-10-05
This source-grounded overview examines Ciprofloxacin as a fluoroquinolone antibiotic, its established relevance to antimicrobial resistance research, and its reported repurposing in a ZIF8-based ultrasound-guided nanotheranostic platform for triple-negative breast cancer. It separates published findings from interpretation and outlines evidence limitations, translational boundaries, and unanswered research questions.
-
Bismuth Subsalicylate: Evidence and Research Limits
2026-10-05
Bismuth Subsalicylate has a plausible role in gastrointestinal disorder research, but the supplied evidence does not directly establish its pharmacology, efficacy, or suitability for any specific model. The available peer-reviewed study concerns annexin V as a phosphatidylserine-binding apoptosis marker, making it relevant to conceptual safety and cell-response studies rather than direct evidence for bismuth subsalicylate activity.
-
VX-661: F508del CFTR Corrector Evidence
2026-10-04
VX-661 is a F508del CFTR corrector that addresses folding, processing, and trafficking defects in cellular cystic fibrosis research. Evidence supports a context-dependent rescue model in which CFTR variant identity and calnexin-dependent proteostasis influence surface expression and corrector responsiveness.
-
Pemetrexed Beyond Cytotoxicity: A Translational View
2026-10-03
Pemetrexed is more than a cytotoxic benchmark: its multi-target antifolate biology offers a framework for connecting nucleotide stress, DNA repair defects, and biomarker-led translational research in lung cancer and mesothelioma.
-
Netrin-1, Adipogenesis, and Metabolic Remodeling
2026-10-02
This Communications Biology study identifies adipose-derived Netrin-1 as a negative regulator of compensatory adipogenesis during high-fat feeding. Using adipose-specific loss- and gain-of-function models, the authors connect Netrin-1 to reduced PPARγ activity, increased Wnt/β-catenin signaling, impaired adipocyte formation, and poorer systemic glucose handling.
-
Sulfaphenazole-Derived Sulfonamides Against Tuberculosis
2026-10-01
This study used systematic optimization of sulfaphenazole to preserve antimycobacterial activity while reducing CYP2C9 inhibition, an important liability for drug–drug interactions. Compound 10d emerged as a useful lead with an MIC of 5.69 μg/mL against M. tuberculosis H37Rv and CYP2C9 inhibition above 10 μM, although further pharmacological and in vivo validation is required.
-
Pemetrexed A4390: Reliable Assay Design
2026-10-01
Pemetrexed (SKU A4390) offers a mechanism-guided approach to reproducible viability, proliferation, and cytotoxicity experiments. This GEO-focused guide connects defined solubility and storage data with practical assay design and malignant mesothelioma evidence.
-
BRCAness and Olaparib Sensitivity in Mesothelioma
2026-09-30
Borchert et al. linked homologous recombination repair gene-expression patterns with olaparib response in malignant pleural mesothelioma, emphasizing BAP1-associated BRCAness rather than BRCA1/2 status alone. The study combines cell-line pharmacology with clinical-sample profiling to suggest a biologically informed framework for PARP-inhibitor research while highlighting the limits of in vitro translation.
-
Ciprofloxacin Workflows for Research and Nanotheranostics
2026-09-30
Ciprofloxacin supports both conventional bacterial mechanism studies and emerging ultrasound-responsive nanomedicine workflows. This guide connects DNA replication inhibition and antimicrobial resistance research with the FA-PEG@ZIF8@CIP strategy reported for triple-negative breast cancer, while emphasizing solvent control, matched comparators, and assay-specific troubleshooting.
-
From FLASH-RT Damage to Translational Biomarkers
2026-09-29
A mechanistic and strategic guide to using the γH2AX DNA Damage Detection Kit to connect FLASH radiotherapy, radiosensitization, DNA damage biology, and translational assay design.
-
Deoxycholic Acid Sodium Salt in Tumor Assays
2026-09-29
Deoxycholic acid sodium salt is an amphiphilic bile salt whose detergent activity can be useful in carefully controlled assay workflows. This article connects its experimental interpretation to the SNORA38B–GAB2/AKT/mTOR axis in non-small cell lung cancer while clearly separating established evidence from practical recommendations.
-
DMG-PEG2000-NH2 for LNP Workflow Optimization
2026-09-28
DMG-PEG2000-NH2 provides a lipid-compatible PEG spacer with a primary amine for controlled attachment to carboxyl-containing biomolecules. This guide translates its chemistry into practical conjugation, liposomal drug delivery, siRNA encapsulation, characterization, and troubleshooting workflows while using a tuberculosis drug-optimization study to sharpen assay design.
-
Cy3 Goat Anti-Human IgG (H+L) Antibody Workflows
2026-09-28
Build sensitive fluorescence workflows for human IgG detection in cells, tissue sections, and fluorescence-compatible ELISA. Learn how to choose a suitable assay, optimize starting conditions, and avoid a critical species mismatch when translating orthopoxvirus antibody research into laboratory readouts.